U.S. Stock Movement | Biotech company City Therapeutics (CTY.US) debuts on the U.S. stock market, rising nearly 24% after the open.

Zhito Finance APP has learned that on Friday, City Therapeutics (CTY.US) listed on the U.S. stock market. As of press time, the stock rose nearly 24% to $22.315. The IPO price was $18. City Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, founded in 2023, focusing on developing a new generation of RNA interference (RNAi) therapies to treat diseases with significant unmet medical needs by inhibiting the expression of specific disease-related proteins. The company's core R&D pipeline includes CITY-FXI for the prevention of thromboembolic diseases, CITY-RBP4 for the treatment of the inherited retinal disease Stargardt disease, and CITY-TFR2 for anemia associated with chronic diseases, among which CITY-FXI has entered Phase I clinical trials. The company was founded by senior experts in the RNAi field, and co-founder and Executive Chairman John Maraganore previously served as CEO of the RNAi pharmaceutical pioneer Alnylam.